Efficacy and safety of narlumosbart, an anti-RANKL monoclonal antibody, in postmenopausal women with osteoporosis: a multi-center, randomized, double-blind, placebo- and active-controlled, phased II study
narlumosbart（一种抗RANKL单克隆抗体）治疗绝经后骨质疏松症女性的疗效和安全性：一项多中心、随机、双盲、安慰剂和活性药物对照的II期研究
期刊:EClinicalMedicine
影响因子:10
doi:10.1016/j.eclinm.2025.103329
Chi, Yue; Li, Yukun; Cheng, Qun; Cai, Hanqing; Zeng, Yuhong; Sheng, Hui; Song, Bing; Li, Hongmei; Shen, Lin; Li, Min; Xing, Ying; Cheng, Mei; Ma, Yujin; Wang, Difei; Zhu, Mei; Lu, Weiping; Yan, Shuang; Zhang, Xueyuan; Yuan, Jing; Yang, Baofang; Li, Jun; Wang, Juan; Wu, Zhufeng; Xia, Weibo
